BDNF and serum S100B levels according the spectrum of structural pathology in chronic pain patients

• Autor(a) principal: Stefani, Luciana Paula Cadore
• Data de Publicação: 2019
• Outros Autores: Leite, Fabrício Maia, Tarragó, Maria da Graça Lopes, Zanette, Simone de Azevedo, Souza, Andressa de, Castro, Stela Maris de Jezus, Caumo, Wolnei
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/195917
• topic: Fator neurotrófico derivado do cérebro; Sensibilização do sistema nervoso central; Osteoartrite; Fibromialgia; Cefaléia do tipo tensional; Estatística médica; Brain-derived neurotrophic factor; S100B; Central sensitization syndrome; Osteoarthritis; Fibromyalgia; Tension headache

Central sensitivity syndrome (CSS) consists of adaptive pathophysiological changes associated with neuroplasticity in some chronic pain disorders. It could be grouped in two main conceptual conditions: one includes those chronic pain patients without overt structural pathology such as fibromyalgia, and the other subgroup includes conditions with recognizable structural abnormalities, both somatic (osteoarthritis) and visceral (endometriosis). In order to understand the role of neuromodulators in CCS we aim to determine whether brain-derived neurotrophic factor (BDNF) and S100B are associated to specific chronic pain disorders. Serum BDNF and S100B were measured in chronic pain women with different diagnosis: 88 with osteoarthritis, 36 with endometriosis, 117 with fibromyalgia, 33 with chronic tension type headache and in 41 healthy controls. ANCOVA analysis followed by heteroscedasticity-consistent covariance matrix was performed to evaluate BDNF and S100B levels, adjusted for depression severity, pain levels and use of analgesics according different pathologies. Serum BDNF concentrations were higher and not different in patients with fibromyalgia and headache, the CSS group without structural pathology. In contrast, the concentrations of S100B were higher in patients with osteoarthritis and endometriosis, in comparison to controls, fibromyalgia and tensional headache patients. This study supports the hypothesis that BDNF and S100B neuromodulators present different serum levels according to the background disease associated to the chronic pain. These have the potential to be studied as markers of active disease or treatment evolution.